Iclusig (ponatinib) — Medica

Initial criteria

• Patient has Philadelphia chromosome-positive acute lymphoblastic leukemia OR patient has ABL-class translocation
• The medication will be used in combination with chemotherapy OR the acute lymphoblastic leukemia is T315I-positive OR patient has tried at least one other tyrosine kinase inhibitor (e.g., imatinib, dasatinib)

Approval duration

1 year